What is a ‘disruptive’ AI medical device? The FDA is updating its guidance

In the era of widespread clinical AI, the US agency is tightening the criteria under which a device can qualify for its fast-track procedure.

The designation of a ‘breakthrough’ medical device grants manufacturers preferential access to FDA teams and fast-track processing of their applications. Designed for truly novel technologies, this designation now faces a new reality: clinical AI is no longer exceptional, and hundreds of authorised algorithms are already in use, particularly in imaging.

The question now facing the agency is therefore one of thresholds. Does an algorithm that detects an anomaly already detectable by an authorised device represent sufficient progress to justify an accelerated pathway, or does it merely improve on what already exists to a marginal extent? The answer directly determines the pace at which new tools reach hospitals, and the level of evidence required before they do so.

The issue goes beyond administrative procedure. A significant proportion of medical AI authorisations are based on comparisons with previous devices rather than on new clinical trials. Tightening the definition of ‘breakthrough’ amounts to deciding where to strike a balance between rapid access to innovation and the requirement for clinical evidence.